get a key
steadybase-$ company IVVD
account_id none on file
legal_name Invivyd, Inc.
ticker IVVD
cik 1832038
domain invivyd.com
entry_point_account_id none on file
name Invivyd Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 25 executives 7 family 0
why_nownone on file
callsnone on file
filings
• Increase in other costs primarily resulted from an increase of $0.5 million in employee related travel expense, $0.2 million in software licensing costs and $0.2 million in rent expense.

filing / Aug 13, 2026 / receipt

• Increase in other costs primarily resulted from an increase of $1.2 million in employee related travel costs, $0.3 million in technology related costs, $0.2 million in conference related costs, $0.2 million in rent expense, and $0.1 million in educational grant costs.

filing / Aug 13, 2026 / receipt

• Increase in personnel related costs resulted from an increase in headcount-related costs; • Increase in professional and consultant fees primarily resulted from an increase of $4.2 million in professional service fees and $3.5 million related to sales and marketing costs, partially offset by $0.1 million in insurance costs; and • Increase in other costs primarily resulted from an increase of $0.5 million in emp

filing / Aug 13, 2026 / receipt

The Company took occupancy of the new dedicated laboratory and office space in December 2022. The amended Newton, MA Lease provided for monthly rental payments, including base rent charges of $ 1.3 million per year.

filing / Aug 13, 2026 / receipt

• Increase in personnel related costs resulted from an increase in headcount-related costs; and • External discovery-related and other costs remained relatively consistent between periods.

filing / Aug 13, 2026 / receipt

In June 2022, the Company entered into a two-year noncancelable agreement for dedicated laboratory and office space in Newton, Massachusetts (the “Newton, MA Lease”), which was amended in September 2022.

filing / Aug 13, 2026 / receipt

• Increase in other costs primarily resulted from an increase of $0.7 million in employee related travel expense, $0.3 million in conference related costs and $0.2 million in technology related costs.

filing / May 14, 2026 / receipt

• Increase in personnel related costs resulted from an increase in headcount-related costs; • Increase in professional and consultant fees resulted from an increase of $3.4 million in professional service fees and $1.7 million related to sales and marketing costs, partially offset by a decrease of $0.1 million in insurance costs; and • Increase in other costs primarily resulted from an increase of $0.7 million in

filing / May 14, 2026 / receipt

The Company took occupancy of the new dedicated laboratory and office space in December 2022. The amended Newton, MA Lease provided for monthly rental payments, including base rent charges of $ 1.3 million per year.

filing / May 14, 2026 / receipt

• our headcount growth and associated costs as we expand our research and development capabilities and build and maintain a commercial infrastructure for product candidates for which we obtain regulatory authorization or approval;

filing / May 14, 2026 / receipt

In June 2022, the Company entered into a two-year noncancelable agreement for dedicated laboratory and office space in Newton, Massachusetts (the “Newton, MA Lease”), which was amended in September 2022.

filing / May 14, 2026 / receipt

Regional Sales Director, Midwest | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4712774006", "remote": true, "category": "sales_expansion", "function": "sales", "location": "Remote (C

company_statement / Sep 14, 2026 / receipt

executives
Ajay Royan director - receipt
David Hering Interim Chief Executive Officer - receipt
Frederick W. Driscoll Interim Chief Financial Officer - receipt
Jane Pritchett Henderson Chief Business Officer - receipt
Jeremy Gowler Interim Chief Executive Officer - receipt
Sara Cotter director - receipt
William Duke Chief Financial Officer - receipt
familynone on file
upcoming
2026-11-05 earnings call scheduled ir
changes
2025-03-26 director, appointed sec_8k
2024-04-12 Interim Chief Executive Officer, appointed sec_8k
2023-09-05 Chief Financial Officer, appointed sec_8k
2023-07-27 director, appointed sec_8k
2022-12-06 Chief Operating Officer, appointed sec_8k
2022-10-13 Interim Chief Financial Officer, appointed sec_8k
2022-03-21 Interim Chief Executive Officer, appointed sec_8k
2022-03-21 Chief Business Officer, appointed sec_8k
2022-02-23 Interim Chief Executive Officer, appointed sec_8k
mcp_package_hint
steadybase-$